To go or not to go in phase 2/3 oncology trials, a critical question with a unified answer
Author:
- 13 March 2023
- journal article
- research article
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 128, 107146
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Interpreting the Regulatory Perspective on Adaptive DesignsStatistics in Biopharmaceutical Research, 2018
- A 2-in-1 adaptive phase 2/3 design for expedited oncology drug developmentContemporary Clinical Trials, 2018
- Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept TrialsClinical Cancer Research, 2014
- Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug DevelopmentStatistics in Biopharmaceutical Research, 2009